Previous 10 | Next 10 |
AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures PR Newswire HAYWARD, Calif. , Jan. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialt...
AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery PR Newswire HAYWARD, Calif. , Jan. ...
AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics AcelRx expands its late-stage development pipeline with acquisition Lowell's lead product, Niyad™ was granted FDA Breakthrough Device Designation and an ICD-10 code from CMS for rei...
AcelRx Pharmaceuticals (NASDAQ:ACRX) announces the publication of real-world data in patients undergoing total hip or total knee replacement showing decreased hospital length of stay and decreased opioid utilization following administration of sublingual sufentanil tablet (SST) to manage acut...
AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery PR Newswire HAYWARD, Calif. , Dec. 15, 2021 /PRNewswire/ --...
AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors PR Newswire HAYWARD, Calif. , Nov. 23, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and...
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2021 Earnings Conference Call November 15, 2021, 8:00 AM ET Company Participants Vincent Angotti – Chief Executive Officer Raffi Asadorian – Chief Financial Officer Pamela P. Palmer – Chief Medical Officer Conference Call Participant...
AcelRx Pharmaceuticals (NASDAQ:ACRX) has announced a ~$14M common stock and warrant offering. The pharmaceutical firm entered into an agreement with two life sciences-focused investment funds, that are existing and new stockholders in AcelRx, for the sale of 17.50M shares of its common stock ...
AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering Investment from leading life sciences investors PR Newswire HAYWARD, Calif. , Nov. 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty...
AcelRx Pharmaceuticals (NASDAQ:ACRX) perks up 3.2% premarket after announcing a merger agreement to acquire privately held, Lowell Therapeutics. Lowell develops Niyad, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney inju...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...